Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 63 of 63 entries
View as:

Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00072787 Org: User:
Start: 10/31/03 End: 05/31/06 Due: 05/31/07

Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02500043 Org: User:
Start: 02/24/16 End: 12/19/19 Due: 12/19/20

Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00652561 Org: User:
Start: 02/28/05 End: 11/30/07 Due: 11/30/08

Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04601857 Org: User:
Start: 01/21/21 End: 08/31/25 Due: 08/31/26

Study of ASTX029 in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03520075 Org: User:
Start: 05/10/18 End: 12/01/25 Due: 12/01/26

Evaluating Patients With Impaired Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT00398424 Org: User:
Start: 02/28/06 End: 03/31/09 Due: 03/31/10

Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00652054 Org: User:
Start: 06/30/05 End: 10/31/07 Due: 10/31/08

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT02503423 Org: User:
Start: 07/31/15 End: 12/31/25 Due: 12/31/26

A Study of TAS1440 With ATRA in Subjects With r/r AML

Phase: N/A Priority: Normal
NCT ID: NCT04282668 Org: User:
Start: 03/15/20 End: 02/12/24 Due: 02/12/25

Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02566772 Org: User:
Start: 03/31/16 End: 04/26/24 Due: 04/26/25

A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

Phase: N/A Priority: Normal
NCT ID: NCT02860546 Org: User:
Start: 08/29/16 End: 09/07/17 Due: 09/07/18

A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00400023 Org: User:
Start: 09/30/06 End: 05/31/07 Due: 05/31/08

Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00651833 Org: User:
Start: 02/28/05 End: 07/31/07 Due: 07/31/08